Published in RNA on February 14, 2011
Progress toward in vivo use of siRNAs-II. Mol Ther (2011) 1.60
Lipid nanoparticles for hepatic delivery of small interfering RNA. Biomaterials (2012) 0.93
Enhanced hepatic delivery of siRNA and microRNA using oleic acid based lipid nanoparticle formulations. J Control Release (2013) 0.88
Tumor vasculature is a key determinant for the efficiency of nanoparticle-mediated siRNA delivery. Gene Ther (2011) 0.86
Small-interfering RNA-eluting surfaces as a novel concept for intravascular local gene silencing. Mol Med (2011) 0.80
Development of a Positive-readout Mouse Model of siRNA Pharmacodynamics. Mol Ther Nucleic Acids (2013) 0.76
RNAi-mediated gene silencing in non-human primates. Nature (2006) 7.60
Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat Biotechnol (2005) 6.40
Short interfering RNAs can induce unexpected and divergent changes in the levels of untargeted proteins in mammalian cells. Proc Natl Acad Sci U S A (2004) 4.85
Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Res (2005) 4.24
Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing's sarcoma. Cancer Res (2005) 3.81
An inverted hexagonal phase of cationic liposome-DNA complexes related to DNA release and delivery. Science (1998) 3.80
Efficient delivery of small interfering RNA to bone-metastatic tumors by using atelocollagen in vivo. Proc Natl Acad Sci U S A (2005) 3.24
Efficient delivery of siRNA for inhibition of gene expression in postnatal mice. Nat Genet (2002) 3.08
Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. Nucleic Acids Res (2004) 3.03
A small interfering RNA targeting vascular endothelial growth factor as cancer therapeutics. Cancer Res (2004) 2.72
RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA in vivo. Gene Ther (2005) 2.68
Improved DNA: liposome complexes for increased systemic delivery and gene expression. Nat Biotechnol (1997) 2.52
Materializing the potential of small interfering RNA via a tumor-targeting nanodelivery system. Cancer Res (2007) 2.30
Small interfering RNAs directed against beta-catenin inhibit the in vitro and in vivo growth of colon cancer cells. Clin Cancer Res (2003) 2.18
Evaluating hypoxia-inducible factor-1alpha as a cancer therapeutic target via inducible RNA interference in vivo. Cancer Res (2005) 1.49
Defining the optimal parameters for hairpin-based knockdown constructs. RNA (2007) 1.48
RNA interference in the mouse vascular endothelium by systemic administration of siRNA-lipoplexes for cancer therapy. Gene Ther (2006) 1.29
Liver-specific knockdown of JNK1 up-regulates proliferator-activated receptor gamma coactivator 1 beta and increases plasma triglyceride despite reduced glucose and insulin levels in diet-induced obese mice. J Biol Chem (2007) 1.24
Safety studies of the intraperitoneal injection of E1A--liposome complex in mice. Gene Ther (1997) 0.81
[Small interference RNAs directed against KDR gene inhibit the proliferation of breast cancer cells in vitro and in vivo]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi (2008) 0.80
An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature (2005) 22.40
Specificity of short interfering RNA determined through gene expression signatures. Proc Natl Acad Sci U S A (2003) 3.74
Structural biology of the Bcl-2 family of proteins. Biochim Biophys Acta (2004) 3.47
Surveillance for recurrent bladder cancer using a point-of-care proteomic assay. JAMA (2006) 3.41
Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737. Cancer Res (2007) 3.24
siRNA-mediated off-target gene silencing triggered by a 7 nt complementation. Nucleic Acids Res (2005) 3.21
Discovery of small molecules that bind to K-Ras and inhibit Sos-mediated activation. Angew Chem Int Ed Engl (2012) 3.09
Detection of bladder cancer using a point-of-care proteomic assay. JAMA (2005) 2.88
Nomogram to predict the benefit of radiation for older patients with breast cancer treated with conservative surgery. J Clin Oncol (2012) 2.85
Druggability indices for protein targets derived from NMR-based screening data. J Med Chem (2005) 2.67
The flowering time regulator CONSTANS is recruited to the FLOWERING LOCUS T promoter via a unique cis-element. New Phytol (2010) 2.63
Multimodality management of urachal carcinoma: the M. D. Anderson Cancer Center experience. J Urol (2003) 2.41
Discovery of potent myeloid cell leukemia 1 (Mcl-1) inhibitors using fragment-based methods and structure-based design. J Med Chem (2012) 2.23
Hexaminolevulinate guided fluorescence cystoscopy reduces recurrence in patients with nonmuscle invasive bladder cancer. J Urol (2010) 2.13
CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma. Proc Natl Acad Sci U S A (2007) 2.11
Activity of the Bcl-2 family inhibitor ABT-263 in a panel of small cell lung cancer xenograft models. Clin Cancer Res (2008) 2.10
Studies leading to potent, dual inhibitors of Bcl-2 and Bcl-xL. J Med Chem (2007) 2.09
Discovery of potent antagonists of the antiapoptotic protein XIAP for the treatment of cancer. J Med Chem (2004) 2.05
DNA methylation and environmental exposures in human hepatocellular carcinoma. J Natl Cancer Inst (2002) 2.04
Evidence supporting preoperative chemotherapy for small cell carcinoma of the bladder: a retrospective review of the M. D. Anderson cancer experience. J Urol (2004) 1.91
Discovery of an orally bioavailable small molecule inhibitor of prosurvival B-cell lymphoma 2 proteins. J Med Chem (2008) 1.85
Identification of Ras-related nuclear protein, targeting protein for xenopus kinesin-like protein 2, and stearoyl-CoA desaturase 1 as promising cancer targets from an RNAi-based screen. Cancer Res (2007) 1.81
Modeling the impact of treatment and screening on U.S. breast cancer mortality: a Bayesian approach. J Natl Cancer Inst Monogr (2006) 1.73
PTP1B antisense oligonucleotide lowers PTP1B protein, normalizes blood glucose, and improves insulin sensitivity in diabetic mice. Proc Natl Acad Sci U S A (2002) 1.73
The basic helix-loop-helix transcription factor PIF5 acts on ethylene biosynthesis and phytochrome signaling by distinct mechanisms. Plant Cell (2007) 1.73
FTY720 demonstrates promising preclinical activity for chronic lymphocytic leukemia and lymphoblastic leukemia/lymphoma. Blood (2007) 1.69
Correlation between CpG methylation profiles and hormone receptor status in breast cancers. Breast Cancer Res (2007) 1.68
A small-molecule inhibitor of Bcl-XL potentiates the activity of cytotoxic drugs in vitro and in vivo. Cancer Res (2006) 1.67
Discovery of a potent inhibitor of the antiapoptotic protein Bcl-xL from NMR and parallel synthesis. J Med Chem (2006) 1.64
A Bayesian approach to jointly modeling toxicity and biomarker expression in a phase I/II dose-finding trial. Biometrics (2005) 1.64
Statistical methods for analyzing right-censored length-biased data under cox model. Biometrics (2009) 1.58
Structure-activity relationship of heterobase-modified 2'-C-methyl ribonucleosides as inhibitors of hepatitis C virus RNA replication. J Med Chem (2004) 1.57
Positional effect of chemical modifications on short interference RNA activity in mammalian cells. J Med Chem (2005) 1.57
Nail gun injuries among construction workers. Appl Occup Environ Hyg (2003) 1.55
Crkl deficiency disrupts Fgf8 signaling in a mouse model of 22q11 deletion syndromes. Dev Cell (2006) 1.55
Growth inhibition and radiosensitization of glioblastoma and lung cancer cells by small interfering RNA silencing of tumor necrosis factor receptor-associated factor 2. Cancer Res (2008) 1.55
Structure of the N-terminal RNA-binding domain of the SARS CoV nucleocapsid protein. Biochemistry (2004) 1.53
Regulation of the Apaf-1/caspase-9 apoptosome by caspase-3 and XIAP. J Biol Chem (2002) 1.52
Solution structure of a Bcl-2 homolog from Kaposi sarcoma virus. Proc Natl Acad Sci U S A (2002) 1.52
Evaluating hypoxia-inducible factor-1alpha as a cancer therapeutic target via inducible RNA interference in vivo. Cancer Res (2005) 1.49
Monitoring late-onset toxicities in phase I trials using predicted risks. Biostatistics (2007) 1.48
Defining the optimal parameters for hairpin-based knockdown constructs. RNA (2007) 1.48
The Bcl-2 inhibitor ABT-263 enhances the response of multiple chemotherapeutic regimens in hematologic tumors in vivo. Cancer Chemother Pharmacol (2010) 1.47
Functional organization of a neural network for aversive olfactory learning in Caenorhabditis elegans. Neuron (2010) 1.43
Neoadjuvant chemotherapy in small cell urothelial cancer improves pathologic downstaging and long-term outcomes: results from a retrospective study at the MD Anderson Cancer Center. Eur Urol (2012) 1.42
Increased apoptosis in metastatic human colonic adenocarcinomas. Cancer Biol Ther (2002) 1.42
Is there a role for surgery in the management of metastatic urothelial cancer? The M. D. Anderson experience. J Urol (2004) 1.39
The Bcl-2/Bcl-X(L)/Bcl-w inhibitor, navitoclax, enhances the activity of chemotherapeutic agents in vitro and in vivo. Mol Cancer Ther (2011) 1.36
A renal mass in the setting of a nonrenal malignancy: When is a renal tumor biopsy appropriate? Cancer (2004) 1.35
ABT-263 and rapamycin act cooperatively to kill lymphoma cells in vitro and in vivo. Mol Cancer Ther (2008) 1.34
Discovery and structure-activity relationship of antagonists of B-cell lymphoma 2 family proteins with chemopotentiation activity in vitro and in vivo. J Med Chem (2006) 1.33
Defining the p53 DNA-binding domain/Bcl-x(L)-binding interface using NMR. FEBS Lett (2004) 1.33
A chemical genomics screen highlights the essential role of mitochondria in HIF-1 regulation. Proc Natl Acad Sci U S A (2008) 1.33
Functional profiling reveals that only a small number of phytochrome-regulated early-response genes in Arabidopsis are necessary for optimal deetiolation. Plant Cell (2006) 1.31
Survivin depletion preferentially reduces the survival of activated K-Ras-transformed cells. Mol Cancer Ther (2007) 1.31
Development of a tightly regulated U6 promoter for shRNA expression. FEBS Lett (2004) 1.30
Increased frequency of ICOS+ CD4 T cells as a pharmacodynamic biomarker for anti-CTLA-4 therapy. Cancer Immunol Res (2013) 1.29
Reversal of multidrug resistance by transferrin-conjugated liposomes co-encapsulating doxorubicin and verapamil. J Pharm Pharm Sci (2007) 1.27
Transcriptomic and genomic evolution under constant cold in Antarctic notothenioid fish. Proc Natl Acad Sci U S A (2008) 1.26
Solution structure of the BHRF1 protein from Epstein-Barr virus, a homolog of human Bcl-2. J Mol Biol (2003) 1.26
Angiotensin receptor subtype AT(1) mediates alveolar epithelial cell apoptosis in response to ANG II. Am J Physiol Lung Cell Mol Physiol (2002) 1.24
Liver-selective glucocorticoid antagonists: a novel treatment for type 2 diabetes. J Med Chem (2004) 1.24
Cancer-testis antigens: expression and correlation with survival in human urothelial carcinoma. Clin Cancer Res (2006) 1.24
p63 expression defines a lethal subset of muscle-invasive bladder cancers. PLoS One (2012) 1.22
Marginal analysis of correlated failure time data with informative cluster sizes. Biometrics (2007) 1.22
Targeted delivery systems for oligonucleotide therapeutics. AAPS J (2009) 1.19
Fragment-based drug discovery using NMR spectroscopy. J Biomol NMR (2013) 1.17
A novel Raji-Burkitt's lymphoma model for preclinical and mechanistic evaluation of CD52-targeted immunotherapeutic agents. Clin Cancer Res (2008) 1.17
Hepatic knockdown of mitochondrial GPAT1 in ob/ob mice improves metabolic profile. Biochem Biophys Res Commun (2006) 1.13
Improvement of xylose fermentation in respiratory-deficient xylose-fermenting Saccharomyces cerevisiae. Metab Eng (2011) 1.12
Prognostic role of detection method and its relationship with tumor biomarkers in breast cancer: the university of Texas M.D. Anderson Cancer Center experience. Cancer Epidemiol Biomarkers Prev (2008) 1.12
Discovery of a potent, selective protein tyrosine phosphatase 1B inhibitor using a linked-fragment strategy. J Am Chem Soc (2003) 1.11
Phytochrome phosphorylation modulates light signaling by influencing the protein-protein interaction. Plant Cell (2004) 1.11
Incidence, predictors, and associated outcomes of atrial fibrillation after kidney transplantation. Clin J Am Soc Nephrol (2005) 1.11
De novo congestive heart failure after kidney transplantation: a common condition with poor prognostic implications. Am J Kidney Dis (2005) 1.09
Discovery and design of novel HSP90 inhibitors using multiple fragment-based design strategies. Chem Biol Drug Des (2007) 1.08
Cost-effectiveness analysis of mammography and clinical breast examination strategies: a comparison with current guidelines. Cancer Epidemiol Biomarkers Prev (2009) 1.08
Nonparametric tests for right-censored data with biased sampling. J R Stat Soc Series B Stat Methodol (2010) 1.07
Approach for targeting Ras with small molecules that activate SOS-mediated nucleotide exchange. Proc Natl Acad Sci U S A (2014) 1.04
T cell–derived inducible nitric oxide synthase switches off Th17 cell differentiation. J Exp Med (2013) 1.03
The proteasome inhibitor bortezomib synergizes with gemcitabine to block the growth of human 253JB-V bladder tumors in vivo. Mol Cancer Ther (2004) 1.03
A high-throughput fluorescence polarization anisotropy assay for the 70N domain of replication protein A. Anal Biochem (2011) 1.03
Maximum Likelihood Estimations and EM Algorithms with Length-biased Data. J Am Stat Assoc (2011) 1.02
Prognostic factors and risk assessment in chronic myelomonocytic leukemia: validation study of the M.D. Anderson Prognostic Scoring System. Leuk Lymphoma (2007) 1.02
Discovery of a potent and selective Bcl-2 inhibitor using SAR by NMR. Bioorg Med Chem Lett (2010) 1.02
Discovery of aminoglycoside mimetics by NMR-based screening of Escherichia coli A-site RNA. J Am Chem Soc (2003) 1.02
Multicomponent cycloadditions: the four-component [5+1+2+1] cycloaddition of vinylcyclopropanes, alkynes, and CO. J Am Chem Soc (2005) 1.01
Pygo2 associates with MLL2 histone methyltransferase and GCN5 histone acetyltransferase complexes to augment Wnt target gene expression and breast cancer stem-like cell expansion. Mol Cell Biol (2010) 1.01
Microtubule-stabilizing agents based on designed laulimalide analogues. Proc Natl Acad Sci U S A (2004) 1.01
Induced expression of B7-H4 on the surface of lung cancer cell by the tumor-associated macrophages: a potential mechanism of immune escape. Cancer Lett (2011) 1.01